Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea. Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation of Agamree and is valued at up to $205m plus royalties. Under the deal, Santhera will be eligib ...

Group 1 - Ocugen's stock rose by over 12% following a licensing agreement with Kwangdong Pharmaceutical, significantly outperforming the S&P 500's 0.5% increase [1] - The licensing deal grants Kwangdong exclusive rights to OCU400 in South Korea, targeting retinitis pigmentosa (RP), a retinal disorder causing vision loss [2] - Ocugen will receive up-front fees and development milestones totaling up to $7.5 million, with additional milestones of $1.5 million for every $15 million in sales through Kwangdong [3][4] Group 2 - The potential market for OCU400 in South Korea is significant, with approximately 7,000 people affected by RP, indicating further market opportunities if the drug is commercialized elsewhere [5] - The company stands to earn a 25% royalty on net sales of OCU400 in South Korea, enhancing its revenue potential [4]